Search

Search Constraints

You searched for: Author/Creator Rossing, P

Search Results

3. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. (3rd October 2022)

4. In patients with type 2 diabetes chronic kidney disease is a modifiable cardiovascular risk factor. (3rd October 2022)

8. The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure. (14th October 2021)